Inhibition of angiotensin II type 1 receptor by candesartan reduces tumor growth and ameliorates fibrosis in colorectal cancer

Tabatabai, Ehsan; Khazaei, Majid; Asgharzadeh, Fereshteh; Nazari, Seyedeh Elnaz; Shakour, Neda; Fiuji, Hamid; Ziaeemehr, Aghigh; Mostafapour, Asma; Parizadeh, Mohammad Reza; Nouri, Mohammad; Hassanian, Seyed Mahdi; Hadizadeh, Farzin; Ferns, Gordon A.; Rahmati, Mohammad; Rahmani, Farzad; Avan, Amir

doi:10.17179/excli2021-3421

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LiCl and the drugs did not affect HEK293T cells transfected with FOPFlash, a reporter in which Tcf-sites are mutated. The inhibition of the Wnt pathway in colon cancer by Candesartan has been previously suggested [ 64 ], while Erlotinib emerged from our screen as a new inhibitor of Wnt/β-catenin signaling. A summary illustration that describes the selection criteria of compounds across the entire screening workflow is provided in Supplemental Fig.…”

Section: Resultsmentioning

confidence: 99%

Zebrafish drug screening identifies Erlotinib as an inhibitor of Wnt/β-catenin signaling and self-renewal in T-cell acute lymphoblastic leukemia

Al-Hamaly,

Cox,

Haney

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Zebrafish drug screening identifies Erlotinib as an inhibitor of Wnt/β-catenin signaling and self-renewal in T-cell acute lymphoblastic leukemia

Al-Hamaly,

Cox,

Haney

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

“…Candesartan decreased the immune suppression function of tumor-associated CD11b+ T cells and decreased their production of VEGF and arginase, and increased interferon-γ synthesis in the lymph nodes of colon-cancer-bearing mice, without having effect on in vivo tumor growth [326]. C. Telmisartan in glioblastoma: Telmisartan was cytotoxic via peroxisome proliferatoractivated receptor gamma (PPAR-γ) agonism in glioblastoma cells in vitro, at low concentrations [327]. Telmisartan-induced inhibition of glioblastoma growth via angiotensin receptor inhibition has been extensively reviewed previously [328].…”

Section: Telmisartanmentioning

confidence: 99%

MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen

Kast¹,

Alfieri

Assi

et al. 2022

Cancers

View full text Add to dashboard Cite

In part one of this two-part paper, we present eight principles that we believe must be considered for more effective treatment of the currently incurable cancers. These are addressed by multidrug adjunctive cancer treatment (MDACT), which uses multiple repurposed non-oncology drugs, not primarily to kill malignant cells, but rather to reduce the malignant cells’ growth drives. Previous multidrug regimens have used MDACT principles, e.g., the CUSP9v3 glioblastoma treatment. MDACT is an amalgam of (1) the principle that to be effective in stopping a chain of events leading to an undesired outcome, one must break more than one link; (2) the principle of Palmer et al. of achieving fractional cancer cell killing via multiple drugs with independent mechanisms of action; (3) the principle of shaping versus decisive operations, both being required for successful cancer treatment; (4) an idea adapted from Chow et al., of using multiple cytotoxic medicines at low doses; (5) the idea behind CUSP9v3, using many non-oncology CNS-penetrant drugs from general medical practice, repurposed to block tumor survival paths; (6) the concept from chess that every move creates weaknesses and strengths; (7) the principle of mass—by adding force to a given effort, the chances of achieving the goal increase; and (8) the principle of blocking parallel signaling pathways. Part two gives an example MDACT regimen, gMDACT, which uses six repurposed drugs—celecoxib, dapsone, disulfiram, itraconazole, pyrimethamine, and telmisartan—to interfere with growth-driving elements common to cholangiocarcinoma, colon adenocarcinoma, glioblastoma, and non-small-cell lung cancer. gMDACT is another example of—not a replacement for—previous multidrug regimens already in clinical use, such as CUSP9v3. MDACT regimens are designed as adjuvants to be used with cytotoxic drugs.

show abstract

Enhancing the Anti-angiogenic Effect of Bevacizumab with ACE Inhibition on mCRC

Erdat

Köksoy

Utkan

2022

J Gastrointest Canc

View full text Add to dashboard Cite

Inhibition of angiotensin II type 1 receptor by candesartan reduces tumor growth and ameliorates fibrosis in colorectal cancer

Cited by 7 publications

References 0 publications

Zebrafish drug screening identifies Erlotinib as an inhibitor of Wnt/β-catenin signaling and self-renewal in T-cell acute lymphoblastic leukemia

Zebrafish drug screening identifies Erlotinib as an inhibitor of Wnt/β-catenin signaling and self-renewal in T-cell acute lymphoblastic leukemia

MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen

Enhancing the Anti-angiogenic Effect of Bevacizumab with ACE Inhibition on mCRC

Contact Info

Product

Resources

About